Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company’s oncology and specialty medicine business through a new globally integrated Commercialization Unit, effective April 1, 2027.
As part of the operational excellence pillar outlined in the new Five-Year Business Plan of Daiichi Sankyo in May 2026, commercialization activities will be centralized and reorganized to drive greater speed and consistency, while optimizing resource management and investment decisions as part of the company’s ambition to become a global top five oncology company by 2035.
In addition to the new Chief Commercialization Officer role, Ken will remain a member of the Board of Directors of Daiichi Sankyo Company, Limited, as well as the Chairman of the Board, President and CEO of Daiichi Sankyo, Inc., the company’s U.S. subsidiary. Ken joined Daiichi Sankyo in 2014 and has served as the Head of the Global Oncology Business for the past five years, responsible for building the commercial capabilities of the company in the U.S. and Europe. During his tenure at Daiichi Sankyo, Ken also served in a dual role from 2016 to 2021 as the President and CEO of American Regent, Inc., a subsidiary of Daiichi Sankyo, while leading the U.S. business for Daiichi Sankyo.
